Ling et al., 2004 - Google Patents
Establishment of modified retroviral vector targeting X-linked severe combined immunodeficiencyLing et al., 2004
View PDF- Document ID
- 1482490412291183693
- Author
- Ling C
- Migita M
- Hayakawa J
- Fukunaga Y
- Publication year
- Publication venue
- Journal of Nippon Medical School
External Links
Snippet
Gene therapy targeting hematopoietic stem cells has been proposed as a potential therapy for numerous genetic disorders affecting hematopoiesis. Moloney murine leukemia retroviral vectors are now widely used for clinical gene transfer into hematopoietic progenitors and …
- 230000001177 retroviral 0 title abstract description 20
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200038457A1 (en) | Il-12 immunotherapy for cancer | |
| Hanawa et al. | Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus–based lentiviral vector system | |
| KR100445712B1 (en) | Constructs to increase virus-mediated DNA transfer and culture medium for them | |
| KR100793625B1 (en) | Viable Cell Population Produced by a Method for Enhancing Virus-Mediated DNA Delivery and Cell Composition Comprising the Same | |
| US20160074533A1 (en) | Vector encoding therapeutic polypeptide and safety elements to clear transduced cells | |
| WO1997011604A9 (en) | Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains | |
| Horn et al. | Stem cell gene transfer—Efficacy and safety in large animal studies | |
| JP2000514284A (en) | Vector with SAR element | |
| Flasshove et al. | Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene | |
| Trobridge et al. | Hematopoietic stem cell transduction and amplification in large animal models | |
| Chu et al. | Retrovirus-mediated gene transfer into human hematopoietic stem cells | |
| CN101070548A (en) | Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains | |
| METZ et al. | Bicistronic and two-gene retroviral vectors for usingMDR1 as a selectable marker and a therapeutic gene | |
| SMITH | Retroviral vector-mediated gene transfer into hematopoietic cells: prospects and issues | |
| Ling et al. | Establishment of modified retroviral vector targeting X-linked severe combined immunodeficiency | |
| WO2020254694A1 (en) | All-in one vector for car and therapeutic effector molecule | |
| LeGuern et al. | Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells | |
| Milan et al. | Activator-dependent and activator-independent defective recombinant retroviruses from bovine leukemia virus | |
| Iwata et al. | Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47 phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR 1) and the p47 phox gene | |
| Dybing et al. | GaLV pseudotyped vectors and cationic lipids transduce human CD34+ cells | |
| Bauer Jr et al. | Transduction of human hematopoietic cells and cell lines using a retroviral vector containing a modified murine CD4 reporter gene | |
| Robert et al. | A SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuria | |
| EP1442057B1 (en) | Use of a half-transporter protein of the abcg-family for selecting cells and in gene therapy | |
| Nagashima et al. | New selective amplifier genes containing c-Mpl for hematopoietic cell expansion | |
| Hanazono et al. | Basic Studies Toward Hematopoietic Stem Cell Gene Therapy |